{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:52Z","timestamp":1740106912620,"version":"3.37.3"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00262-018-2163-7","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T07:48:03Z","timestamp":1524728883000},"page":"1329-1330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to \u201cImmune-mediated cholangitis: is it always nivolumab\u2019s fault?\u201d"],"prefix":"10.1007","volume":"67","author":[{"given":"Jumpei","family":"Kashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-0149","authenticated-orcid":false,"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"2163_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, Chiba K (2018) Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 67:61\u201365. \n                    https:\/\/doi.org\/10.1007\/s00262-017-2062-3","journal-title":"Cancer Immunol Immunother"},{"key":"2163_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2159-3","author":"F Gelsomino","year":"2018","unstructured":"Gelsomino F, Vitale G, Ardizzoni A (2018) Immune-mediated cholangitis: is it always nivolumab\u2019s fault? Cancer Immunol Immunother \n                    https:\/\/doi.org\/10.1007\/s00262-018-2159-3","journal-title":"Cancer Immunol Immunother"},{"key":"2163_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdx422.005","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671\u2013672. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw649","journal-title":"Ann Oncol"},{"key":"2163_CR4","doi-asserted-by":"publisher","first-page":"529536","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529\u2013536. \n                    https:\/\/doi.org\/10.1007\/s10637-017-0453-0","journal-title":"Invest New Drugs"},{"key":"2163_CR5","doi-asserted-by":"publisher","first-page":"A35A36","DOI":"10.1016\/j.cgh.2017.03.026","volume":"15","author":"K Kubo","year":"2017","unstructured":"Kubo K, Kato M, Mabe K (2017) Nivolumab-associated colitis mimicking ulcerative colitis. Clin Gastroenterol Hepatol 15:A35\u2013A36. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2017.03.026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2163_CR6","doi-asserted-by":"publisher","first-page":"536542","DOI":"10.1007\/s00534-012-0521-y","volume":"19","author":"H Ohara","year":"2012","unstructured":"Ohara H, Okazaki K, Tsubouchi H et al (2012) Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepato-Biliary-Pancreat Sci 19:536\u2013542. \n                    https:\/\/doi.org\/10.1007\/s00534-012-0521-y","journal-title":"J Hepato-Biliary-Pancreat Sci"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2163-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T19:27:12Z","timestamp":1556220432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2163-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2163"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2163-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2018,4,26]]},"assertion":[{"value":"5 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}